Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.50 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047532 | 0.83 | HDAC1 (0.44) | HDAC1SCD | |
| SCHEMBL14047530 | 0.80 | HDAC1 (0.36) | HDAC1SCDRAB9A | |
| SCHEMBL14047416 | 0.76 | HDAC1 (0.41) | HDAC1SCDKDM4EALDH1A1 | |
| SCHEMBL14047539 | 0.74 | SCD (0.53) | HDAC1SCDKDM4EALDH1A1 | |
| SCHEMBL14047400 | 0.74 | SCD (0.57) | HDAC1SCDRAB9AALDH1A1 | |
| SCHEMBL14047625 | 0.74 | SCD (0.57) | HDAC1SCDRAB9AALDH1A1 | |
| SCHEMBL14047399 | 0.72 | CHRM2 (0.41) | SCD | |
| SCHEMBL14047595 | 0.72 | SCD (0.56) | HDAC1SCDALDH1A1 | |
| SCHEMBL244306 | 0.71 | SCD (0.65) | HDAC1SCDALDH1A1 | |
| SCHEMBL14047421 | 0.71 | SCD (0.59) | HDAC1SCDRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |